Closing
Do SGLT2 inhibitors improve neuropathy, eye & foot versus placebo?
Mostly studied in type 2 & unspecified diabetes.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2…NCT07723820 · not yet recruiting · started 2026
- Clinical Study on the Efficacy of Oral Dapagliflozin Combined With Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Patients With Diabetic…NCT06845163 · recruiting · started 2025
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · recruiting · started 2024
- SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled,…NCT06054035 · recruiting · started 2023
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · active not recruiting · started 2021
The evidence so far
- Registered trials
- 16
- With posted results
- 2
- Published papers
- 1
Of 1 decided analyses: 0 favor sglt2 inhibitors, 1 find no difference, 0 favor the comparator.
Papers
- The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.Trial report · 2022
Trials
- Evaluation of the Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Diabetic Retinopathy in Patients With Type 2 Diabetes MellitusNCT05310916
- Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)NCT07723820
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes MellitusNCT02863328 · 1 posted result
- Empagliflozin in Early Diabetic Kidney DiseaseNCT03173963
- Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 DiabetesNCT03136484 · 1 posted result
- A Multicenter, Register-based, Randomized, Controlled Trial Comparing Dapagliflozin With Metformin Treatment in Early Stage Type 2 Diabetes Patients by Assessing Mortality and Macro- and Microvascular ComplicationsNCT03982381
- A Phase IV, Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study on the Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Individuals With Type 2 DiabetesNCT02932436
- A Randomized, Allocation-concealed, Assessor-blinded, Parallel-group Trial Evaluating the Association Between Erectile Dysfunction and Left Ventricular Diastolic Dysfunction and Comparing the Effects of Tadalafil, SGLT2 Inhibitors, and Their Combination in Patients With Metabolic Syndrome.NCT07563647